Mtbvac Tuberculosis Vaccine

  • 27 Mar 2024

On 24th March, Bharat Biotech commenced clinical trials for Mtbvac, the first TB vaccine derived from a human source.

  • Mtbvac developed for improved efficacy over BCG in newborns and prevention in adults.
  • Trials conducted in collaboration with Biofabri; pivotal trial planned for 2025.
  • India, with a high TB burden, crucial for testing adult and adolescent vaccines.
  • Mtbvac marks significant progress in the quest for a more effective TB vaccine.
  • Phase-3 clinical trials comparing Mtbvac with BCG initiated in newborns.